ABBV · News · 20261104N

Licensing / Collaboration Deals

AbbVie Inc. · 2026-11-04 · Importance 45 · Surprise 42 · In source text

AbbVie obtained exclusive worldwide rights to develop and commercialize Nxera Pharma’s NXE0033744 EP4 receptor agonist program for inflammatory bowel disease. The agreement provides for a $100 million upfront cash payment and up to $1.37 billion in development and commercial milestone payments, plus tiered royalties. The investigational oral small molecule has completed Phase 1 testing and is intended to expand AbbVie’s immunology portfolio alongside Skyrizi and Rinvoq.

Key facts

• AbbVie’s exclusive global license agreement with Nxera includes a US$100 million upfront payment to Nxera and eligibility for up to US$1.37 billion in development and commercial milestone payments, plus tiered royalties. source
• AbbVie licensed Nxera Pharma’s EP4 receptor agonist program for inflammatory bowel disease, with potential milestone payments of up to $1.37 billion in addition to a $100 million upfront cash payment. source
• AbbVie’s licensing agreement with Nxera for NXE0033744 was reported as potentially worth up to $1.5 billion. source
• AbbVie’s exclusive global licensing deal with Nxera for NXE0033744 was reported as worth up to $1.38 billion. source
• AbbVie entered an exclusive global license agreement with Nxera Pharma for its EP4 agonist program, including NXE0033744, for inflammatory bowel disease. source
• AbbVie’s license from Nxera grants exclusive global rights to develop and commercialize NXE0033744, an experimental therapy for inflammatory bowel disease that targets Nxera’s EP4 receptor. source
• AbbVie’s license from Nxera covers NXE0033744, a novel small-molecule EP4 receptor agonist for inflammatory bowel disease. source
• NXE0033744, which AbbVie licensed from Nxera, is an oral small molecule that has completed Phase 1 testing and is designed to work locally in the GI tract. source

Impact estimates